1
|
De Wit R, Vaughn D, Fradet Y, Fong L, Vogelzang N, Climent Duran M, Necchi A, Petrylak D, Gerritsen W, Gurney H, Quinn D, Culine S, Sternberg C, Bajorin D, Choueiri T, Xu J, Imai K, Homet Moreno B, Bellmunt J, Lee JL. 1747P Impact of prior chemotherapy (Chemo) on pembrolizumab (Pembro) response in urothelial cancer (UC): Exploratory analysis of the phase III KEYNOTE-045 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
2
|
Antonarakis E, Piulats J, Gross-Goupil M, Goh J, Vaishampayan U, De Wit R, Alanko T, Fukasawa S, Tabata K, Feyerabend S, Berger R, Ojamaa K, Hoimes C, Sezer A, Omlin A, Yachnin J, Niu C, Poehlein C, Schloss C, de Bono J. 611P Pembrolizumab (pembro) monotherapy for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Updated analyses with 4 years of follow-up from cohorts 1-3 of the KEYNOTE-199 study. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1124] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
3
|
Mout L, Van Royen M, De Ridder C, Stuurman D, Marques R, De Geer W, Van De Werken H, Mathijssen R, De Wit R, Lolkema M, Van Weerden W. Cabazitaxel efficacy is strongly enhanced by continued Androgen Receptor Targeted Agents (ARTA) in Castration-Resistant Prostate Cancer (CRPC). Eur Urol 2021. [DOI: 10.1016/s0302-2838(21)00824-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
4
|
Boormans J, De Wit R, Kulkarni G, Uchio E, Roumiguié M, Krieger L, Singer E, Bajorin D, Kamat A, Grivas P, Seo H, Nishiyama H, Konethy B, Saretsky T, Li H, Nam K, Kapadia E, Balar A. Updated follow-up from KEYNOTE-057: Phase 2 study of pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guérin (BCG). EUR UROL SUPPL 2020. [DOI: 10.1016/s2666-1683(20)33372-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Delanoy N, Robbrecht D, Fizazi K, Mercier F, Sartor O, De Wit R, Oudard S. Pain progression at initiation of chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: A post-hoc analysis of FIRSTANA. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz248.016] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
6
|
Castellano D, Grivas P, Plimack E, Balar A, O’Donnell P, Bellmunt J, Powles T, Hahn N, De Wit R, Bajorin D, Ellison M, Frenkl T, Keefe S, Vuky J. Pembrolizumab (pembro) as first-line therapy in elderly patients (pts) with poor performance status with cisplatin-ineligible advanced urothelial cancer (UC): Results from Keynote-052. ACTA ACUST UNITED AC 2018. [DOI: 10.1016/s1569-9056(18)30938-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
7
|
Bellmunt J, Kerst J, Vázquez F, Morales-Barrera R, Grande E, Medina A, González Graguera M, Rubio G, Anido U, Fernández Calvo O, González-Billalabeitia E, Van den Eertwegh A, Pujol E, Perez-Gracia J, González Larriba J, Collado R, Los M, Maciá S, De Wit R. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN). Ann Oncol 2017; 28:1517-1522. [DOI: 10.1093/annonc/mdx186] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2017] [Indexed: 12/17/2022] Open
|
8
|
Powles T, Bellmunt J, Castellano D, O’Donnell P, Grivas P, Vuky J, Plimack E, Hahn N, Balar A, Pang L, Savage M, Perini R, Keefe S, Bajorin D, De Wit R. Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052. ACTA ACUST UNITED AC 2017. [DOI: 10.1016/s1569-9056(17)30236-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
9
|
Meisel A, Vogt D, De Wit R, De Bono J, Sartor O, Stenner-Liewen F. 2571 A high baseline neutrophil count may predict poor prognostic outcome in mCRPC: A post-hoc analysis of the TROPIC phase III trial. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31390-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
10
|
Onstenk W, Sieuwerts A, Kraan J, Van M, Nieuweboer A, Mathijssen R, Hamberg P, Meulenbeld H, DeLaere B, Dirix L, Van Soest R, Lolkema M, Martens J, Van Weerden W, Jenster G, Foekens J, De Wit R, Sleijfer S. 2575 Presence of androgen receptor splice variants in circulating tumor cells and response to cabazitaxel in castration-resistant prostate cancer. Eur J Cancer 2015. [DOI: 10.1016/s0959-8049(16)31394-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
11
|
Schat H, Ouborg J, De Wit R. Life history and plant architecture: size-dependent reproductive allocation in annual and biennialCentauriumspecies. ACTA ACUST UNITED AC 2015. [DOI: 10.1111/j.1438-8677.1989.tb02041.x] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- H. Schat
- Biologisch Laboratorium Vrije Universiteit; De Boelelaan 1087 1081 HV Amsterdam The Netherlands
| | - J. Ouborg
- Biologisch Laboratorium Vrije Universiteit; De Boelelaan 1087 1081 HV Amsterdam The Netherlands
| | - R. De Wit
- Biologisch Laboratorium Vrije Universiteit; De Boelelaan 1087 1081 HV Amsterdam The Netherlands
| |
Collapse
|
12
|
Meisel A, von Felten S, de Bono J, De Wit R, Sartor O, Stenner-Liewen F. Early Neutropenia is Associated with Survival in Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) When Treated with Cabazitaxel: an Analysis of Tropic Phase III Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
van Soest R, Templeton A, Eisenberger M, Mercier F, Tannock I, De Wit R. The Impact of the Derived Neutrophil to Lymphocyte Ratio and Duration of Initial Androgen Deprivation Therapy (Adt) on Survival of Men with Metastatic Castration-Resistant Prostate Cancer (Mcrpc) Receiving First-Line Chemotherapy: Data from Two Randomized Phase III Trials. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu336.34] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
14
|
Beyer J, Albers P, Altena R, Aparicio J, Bokemeyer C, Busch J, Cathomas R, Cavallin-Stahl E, Clarke NW, Claßen J, Cohn-Cedermark G, Dahl AA, Daugaard G, De Giorgi U, De Santis M, De Wit M, De Wit R, Dieckmann KP, Fenner M, Fizazi K, Flechon A, Fossa SD, Germá Lluch JR, Gietema JA, Gillessen S, Giwercman A, Hartmann JT, Heidenreich A, Hentrich M, Honecker F, Horwich A, Huddart RA, Kliesch S, Kollmannsberger C, Krege S, Laguna MP, Looijenga LHJ, Lorch A, Lotz JP, Mayer F, Necchi A, Nicolai N, Nuver J, Oechsle K, Oldenburg J, Oosterhuis JW, Powles T, Rajpert-De Meyts E, Rick O, Rosti G, Salvioni R, Schrader M, Schweyer S, Sedlmayer F, Sohaib A, Souchon R, Tandstad T, Winter C, Wittekind C. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2012; 24:878-88. [PMID: 23152360 PMCID: PMC3603440 DOI: 10.1093/annonc/mds579] [Citation(s) in RCA: 252] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
In November 2011, the Third European Consensus Conference on Diagnosis and Treatment of Germ-Cell Cancer (GCC) was held in Berlin, Germany. This third conference followed similar meetings in 2003 (Essen, Germany) and 2006 (Amsterdam, The Netherlands) [Schmoll H-J, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ-cell cancer: a report of the European Germ-Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1377-1399; Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008; 53: 478-496; Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ-cell cancer: a report of the second meeting of the European Germ-Cell Cancer Consensus group (EGCCCG): part II. Eur Urol 2008; 53: 497-513]. A panel of 56 of 60 invited GCC experts from all across Europe discussed all aspects on diagnosis and treatment of GCC, with a particular focus on acute and late toxic effects as well as on survivorship issues. The panel consisted of oncologists, urologic surgeons, radiooncologists, pathologists and basic scientists, who are all actively involved in care of GCC patients. Panelists were chosen based on the publication activity in recent years. Before the meeting, panelists were asked to review the literature published since 2006 in 20 major areas concerning all aspects of diagnosis, treatment and follow-up of GCC patients, and to prepare an updated version of the previous recommendations to be discussed at the conference. In addition, ∼50 E-vote questions were drafted and presented at the conference to address the most controversial areas for a poll of expert opinions. Here, we present the main recommendations and controversies of this meeting. The votes of the panelists are added as online supplements.
Collapse
Affiliation(s)
- J Beyer
- Department of Hematology and Oncology, Vivantes Klinikum Am Urban, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Saad F, Akaza H, Eisenberger MA, Nelson J, Scher HI, Suzuki K, Wirth M, Webb IJ, Wang J, MacLean D, De Wit R. A phase III, randomized study of the investigational agent TAK-700 plus prednisone for patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.tps184] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
De Wit R, Skoneczna IA, Gedske Daugaard K, de Santis M, Garin A, Aass N, Witjes JA, Albers P, White J, Germa-Lluch JR, Osanto S, Marreaud S, Collette L. A randomized phase III study comparing paclitaxel-BEP (T-BEP) to standard BEP in patients with in intermediate prognosis germ cell cancer (GCC): An intergroup study of EORTC, German TCSG/AUO, MRC, and Spanish GCC group (EORTC 30983). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4509] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Meulenbeld HJ, van Werkhoven ED, Coenen JLLM, Creemers G, Loosveld OJL, De Jong PC, Ten Tije AJ, Fossa SD, Polee M, Gerritsen WR, Dalesio O, De Wit R. Randomized phase III study of docetaxel with or without risedronate in patients with bone metastases from castration-resistant prostate cancer (CRPC): The Netherlands Prostate Study (NePro). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Seruga B, Horgan AM, Pond GR, Alibhai SMH, Amir E, De Wit R, Eisenberger MA, Tannock I. Tolerability and efficacy of chemotherapy in older men with metastatic castrate-resistant prostate cancer (mCRPC) in the TAX 327 trial. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4530] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Pond GR, Armstrong AJ, Wood BA, Brookes M, Leopold LH, Berry WR, De Wit R, Eisenberger MA, Tannock I, Sonpavde G. Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4582] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Bleuse JP, Meulenbeld HJ, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, De Wit R. Randomized phase II study of danusertib (D) in second-line metastatic castration-resistant prostate cancer (CRPC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.4628] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Sonpavde G, Pond GR, Berry WR, De Wit R, Eisenberger MA, Tannock I, Armstrong AJ. Association between radiographic response and overall survival in men with metastatic castration-resistant prostate cancer receiving chemotherapy. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.7_suppl.118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
118 Background: In men with metastatic castration resistant prostate cancer (CRPC),the association of measurable tumor responses with overall survival (OS) is unknown. We retrospectively evaluated the TAX327 phase III trial to study this relationship. Methods: Eligible patients for this analysis included those with WHO-defined measurable metastatic disease randomized to receive either docetaxel or mitoxantrone. OS was estimated using the Kaplan-Meier method and the prognostic relationship of WHO-defined radiologic response with OS was performed using Cox proportional hazards regression. Landmark analyses evaluated survival from baseline and 2, 3, 4 and 6 months after baseline. Results: Four hundred and twelve patients enrolled on the TAX327 trial had measurable tumors. Thirty-seven patients exhibited a complete or partial objective response (CR/PR, 9.0%), 116 had stable disease (SD, 28.2%), 99 had progressive disease (PD,24%) and 160 (38.8%) did not have a post-baseline objective assessment. Partial responders demonstrated longer median OS (29.0 months) than patients with SD (22.1 months), or those with PD (10.8 months) or those who were not assessed (12.7 months). These results remained after landmark analysis. We found a significant association between ≥30% PSA declines and radiologic response, with ≥30% PSA declines occurring in all patients with CR/PR, 79.8% of patients with SD and 34.4% with PD. Radiologic response remained a significant but modest post-treatment prognostic factor for OS after adjusting for treatment, pain-response and ≥30% PSA-decline (p=0.009). Conclusions: In men with metastatic CRPC and measurable disease receiving chemotherapy, objective tumor response was prognostic for OS, and appears to complement PSA assessment. [Table: see text]
Collapse
Affiliation(s)
- G. Sonpavde
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - G. R. Pond
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - W. R. Berry
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - R. De Wit
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - M. A. Eisenberger
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - I. Tannock
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| | - A. J. Armstrong
- Texas Oncology, Baylor College of Medicine, Houston, TX; McMaster University, Hamilton, ON, Canada; Cancer Centers of North Carolina, Cary, NC; Erasmus University Medical Center, Rotterdam, Netherlands; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; Division of Medical Oncology and Hematology, Princess Margaret Hospital and University of Toronto, Toronto, ON, Canada; Duke University Medical Center, Durham, NC
| |
Collapse
|
22
|
Daugaard G, Skoneczna I, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Lluch JRG, Bokemeyer C, Schmoll HJ. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). Ann Oncol 2010; 22:1054-1061. [PMID: 21059637 DOI: 10.1093/annonc/mdq575] [Citation(s) in RCA: 95] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND To compare the efficacy of one cycle of standard dose cisplatin, etoposide, and ifosfamide (VIP) plus three cycles of high-dose VIP followed by stem-cell infusion [high-dose chemotherapy (HD-CT arm)] to four cycles of standard cisplatin, etoposide, and bleomycin (BEP) in patients with poor-prognosis germ-cell cancer (GCC). PATIENT AND METHODS Patients with poor-prognosis GCC were assigned to receive either BEP or VIP followed by HD-CT. To show a 15% improvement in a 1-year failure-free survival (FFS), the study aimed to recruit 222 patients but closed with 137, due to slow accrual. RESULTS One hundred thirty-one patients were included in this analysis. The complete response rates in the HD-CT and in the BEP arm did not differ: (intention to treat) 44.6% versus 33.3% (P = 0.18). There was no difference in FFS between the two treatment arms (P = 0.057, 66 events). At 2 years, the FFS rate was 44.8% [95% confidence interval (CI) 32.5-56.4] and 58.2%, respectively (95% CI 48.0-71.9); but this 16.3% (standard deviation 7.5%) difference was not statistically significant (P = 0.060). Overall survival did not differ between the two groups (log-rank P > 0.1, 47 deaths). CONCLUSION This study could not demonstrate that high-dose chemotherapy given as part of first-line therapy improves outcome in patients with poor-prognosis GCC.
Collapse
Affiliation(s)
- G Daugaard
- Department of Oncology, Rigshospitalet, Copenhagen, Denmark.
| | - I Skoneczna
- Department of Urology, Chemotherapy Unit, Maria Sklodowska-Curie Memorial Center, Warsaw, Poland
| | - N Aass
- Department of Oncology, Oslo University Hospital and University of Oslo, Oslo, Norway
| | - R De Wit
- Department Medical Oncology, Erasmus University Hospital, Rotterdam, The Netherlands
| | - M De Santis
- LBI-ACR VIEnna and ACR-ITR VIEnna/CEADDP-Kaiser Franz Josef-Spital, Vienna, Austria
| | - H Dumez
- Department of Oncology, University Hospitals, Leuven, Belgium
| | - S Marreaud
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - L Collette
- European Organization for Research and Treatment of Cancer Headquarters, Brussels, Belgium
| | - J R G Lluch
- Institut Català d'Oncologia, Htal. Duran i Reynals, Hòspitalet Barcelona, Barcelona, Spain
| | - C Bokemeyer
- Department of Oncology, Hematology and Bone Marrow Transplantation with Section Pneumology, Hubertus Wald Cancer Center (UCCH), University Medical Center Hamburg Eppendorf, Hamburg
| | - H J Schmoll
- Department of Oncology and Hematology, Martin Luther University, Halle, Germany
| |
Collapse
|
23
|
Daugaard G, Skoneczna IA, Aass N, De Wit R, De Santis M, Dumez H, Marreaud S, Collette L, Bokemeyer C, Schmoll H. A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, ifosfamide (VIP) plus stem cell support in males with poor prognosis germ cell cancer (GCC): An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4512] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
24
|
Scher HI, Chi KN, De Wit R, Berry WR, Albers P, Henick B, Venner P, Heidenreich A, Chu L, Heller G. Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4509] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Niraula S, Tannock I, Pond GR, De Wit R, Eisenberger MA, Joshua AM. Influence of concurrent medications on outcomes of men with prostate cancer included in the TAX327 study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4686] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Pond GR, Sonpavde G, Berry WR, De Wit R, Armstrong AJ, Eisenberger MA, Tannock I. Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.4637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Boyne J, Ramaekers B, De Wit R, Gorgels A, Vrijhoef H. 146 Poster Moderated Patients Telemonitored for Heart Failure: Adherence to Medication and Non-Pharmacological Recommendations. Eur J Cardiovasc Nurs 2010. [DOI: 10.1016/s1474-5151(10)60107-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- J.J.J. Boyne
- University Hospital Maastricht, Maastricht, Netherlands
| | | | - R. De Wit
- University Maastricht, Maastricht, Netherlands
| | | | | |
Collapse
|
28
|
De Wit R. 157 INVITED Chemotherapy developments in hormone refractory prostate cancer, ongoing trials in early and advanced disease. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70271-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
29
|
Affiliation(s)
- E. S. P. Das
- a Engineering Materials Group, Mechanical Engineering Department , University of Maryland , College Park , Maryland , 20742 , U.S.A
- c Materials Science Division, Argonne National Laboratory , Argonne , Illinois 60439 , U.S.A
| | - M. J. Marcinkowski
- a Engineering Materials Group, Mechanical Engineering Department , University of Maryland , College Park , Maryland , 20742 , U.S.A
| | - R. W. Armstrong
- a Engineering Materials Group, Mechanical Engineering Department , University of Maryland , College Park , Maryland , 20742 , U.S.A
| | - R. De Wit
- b Metallurgy Division , Institute for Materials Research, National Bureau of Standards , Washington , D.C. 20234 , U.S.A
| |
Collapse
|
30
|
Berthold DR, Pond G, De Wit R, Eisenberger MA, Tannock IF. Association of pain and quality of life (QOL) response with PSA response and survival of patients (pts) with metastatic hormone refractory prostate cancer (mHRPC) treated with docetaxel or mitoxantrone in the TAX-327 study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4516] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4516 Background: The TAX-327 study compared 3 weekly docetaxel (D3), weekly docetaxel (D1) or mitoxantrone (M), each with prednisone (P) for 1006 pts with mHRPC. Survival and symptom control were superior following D3+P as compared to M+P (Tannock et al, NEJM 2004;351;1502–12). Here we investigate associations between pain and QOL response with PSA response and survival. Methods: Pts were evaluated for pain, PSA and QOL at baseline and 3 weekly during treatment. Pain response (pts with initial pain) was defined by ≥ 2-point reduction in Present Pain Intensity (PPI) with no increase in analgesic score (AS) or ≥ 50% in AS with no increase in PPI. PSA response required ≥ 50% reduction in PSA from baseline. QOL response required ≥ 16-point reduction in FACT-P score (range: 0–156). Responses were confirmed ≥ 3 weeks later. Results: There were414 pts assessable for both pain and PSA response: PSA response was seen in 52.4% of 124 pts with pain response and 28.3% of 290 pts without pain response (p < 0.001). There were 704 pts evaluable for both QOL and PSA response: PSA response occurred in 56.5% of 147 pts with QOL response and 37.5% of 557 pts without QOL response (p < 0.001). The table shows associations of pain or QOL response and survival. Landmark analysis will be presented at the meeting. After adjustment for PSA and QOL response, pain response was an independent predictor of survival (HR = 0.47, p = 0.003). Conclusions: Pain and QOL response were associated with PSA response and pain response was an independent predictor of survival. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- D. R. Berthold
- Princess Margaret Hospital, Toronto, ON, Canada; Erasmus University Medical Center, Rotterdam, The Netherlands; Johns Hopkins University, Baltimore, MD
| | - G. Pond
- Princess Margaret Hospital, Toronto, ON, Canada; Erasmus University Medical Center, Rotterdam, The Netherlands; Johns Hopkins University, Baltimore, MD
| | - R. De Wit
- Princess Margaret Hospital, Toronto, ON, Canada; Erasmus University Medical Center, Rotterdam, The Netherlands; Johns Hopkins University, Baltimore, MD
| | - M. A. Eisenberger
- Princess Margaret Hospital, Toronto, ON, Canada; Erasmus University Medical Center, Rotterdam, The Netherlands; Johns Hopkins University, Baltimore, MD
| | - I. F. Tannock
- Princess Margaret Hospital, Toronto, ON, Canada; Erasmus University Medical Center, Rotterdam, The Netherlands; Johns Hopkins University, Baltimore, MD
| |
Collapse
|
31
|
Eisenberger MA, De Wit R, Berry W, Bodrogi I, Pluzanska A, Chi K, Oudard S, Christine T, James N, Tannock I. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.4] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. A. Eisenberger
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - R. De Wit
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - W. Berry
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - I. Bodrogi
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - A. Pluzanska
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - K. Chi
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - S. Oudard
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - T. Christine
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - N. James
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| | - I. Tannock
- Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Erasmus University, Rotterdam, Netherlands; US Oncology, Raleigh, NC; Orszagos Onkologiai Intezet, Budapest, Hungary; Onkologiczny Klinika Chemotherapii, Lodz, Poland; BC Cancer Agency, Vancouver, BC, Canada; Hopital Europeen Georges Pompidou, Paris, France; Institute Gustave Roussy, Villejuif, France; Queen Elizabeth Hospital, Edgbaston, United Kingdom; Princess Margaret Hospital, Toronto, ON, Canada
| |
Collapse
|
32
|
De Wit R, Van Dam F. Improving the quality of pain treatment by a tailored pain education program for cancer patients in chronic pain. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81525-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
33
|
De Wit R, Hoek FJ, Bakker PJ, Veenhof CH. The value of MCA, CA 15-3, CEA and CA-125 for discrimination between metastatic breast cancer and adenocarcinoma of other primary sites. J Intern Med 1991; 229:463-6. [PMID: 2040873 DOI: 10.1111/j.1365-2796.1991.tb00376.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
MCA, CA 15-3, CEA and CA 125 were determined in the serum of 49 patients with metastatic breast cancer and 38 patients with metastatic adenocarcinoma of other primary sites. By using the 99th percentile of the normal value distribution as the cut-off point, the positive predictive value (PV+) was found to be 85% (95% CI 76-94) for MCA, and 71% (95% CI 61-81) for CA 15-3. When receiver-operating-characteristic (ROC) curves were constructed, the PV+ for CA 15-3 was increased to 82% (95% CI 72-92), using 60 U ml-1 as the cut-off point. With the exception of two patients who had a slightly elevated MCA, MCA and CA 15-3 identified the same patients with breast cancer. By combining a positive MCA or CA 15-3 with a negative CEA and CA 125, further improvement of the PV+ could be achieved; 100% (95% CI 91-100). We conclude that MCA and CA 15-3 may play a useful role in discrimination between patients with metastatic breast cancer and those with adenocarcinoma of other primary sites.
Collapse
Affiliation(s)
- R De Wit
- Department of Medicine, Academic Medical Centre, Amsterdam, The Netherlands
| | | | | | | |
Collapse
|
34
|
Naus D, Bass B, Keeney-Walker J, Fields R, De Wit R, Low S. HSST wide-plate test results and analysis. Nuclear Engineering and Design 1990. [DOI: 10.1016/0029-5493(90)90030-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|